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Abstract
Lysosomal storage disorders (LSDs) are a large group of more than 50 different inherited metabolic diseases
which, in the great majority of cases, result from the defective function of specific lysosomal enzymes and, in few
cases, of non-enzymatic lysosomal proteins or non-lysosomal proteins involved in lysosomal biogenesis. The
progressive lysosomal accumulation of undegraded metabolites results in generalised cell and tissue dysfunction,
and, therefore, multi-systemic pathology. Storage may begin during early embryonic development, and the clinical
presentation for LSDs can vary from an early and severe phenotype to late-onset mild disease. The diagnosis of
most LSDs—after accurate clinical/paraclinical evaluation, including the analysis of some urinary metabolites—is
based mainly on the detection of a specific enzymatic deficiency. In these cases, molecular genetic testing (MGT)
can refine the enzymatic diagnosis. Once the genotype of an individual LSD patient has been ascertained, genetic
counselling should include prediction of the possible phenotype and the identification of carriers in the family at
risk. MGT is essential for the identification of genetic disorders resulting from non-enzymatic lysosomal protein
defects and is complementary to biochemical genetic testing (BGT) in complex situations, such as in cases of
enzymatic pseudodeficiencies. Prenatal diagnosis is performed on the most appropriate samples, which include
fresh or cultured chorionic villus sampling or cultured amniotic fluid. The choice of the test—enzymatic and/or
molecular—is based on the characteristics of the defect to be investigated. For prenatal MGT, the genotype of
the family index case must be known. The availability of both tests, enzymatic and molecular, enormously
increases the reliability of the entire prenatal diagnostic procedure. To conclude, BGT and MGTare mostly
complementary for post- and prenatal diagnosis of LSDs. Whenever genotype/phenotype correlations are
available, they can be helpful in prognosis and in making decisions about therapy.
Keywords: lysosomal storage disorders, biochemical analysis, molecular analysis, laboratory diagnosis, pseudodeficiency,
activator proteins, biobanking
Introduction
Although the first clinical descriptions of patients with
lysosomal storage disorders (LSDs) were reported at
the end of the nineteenth century by Warren Tay
(1881)1 and Bernard Sachs (1887; Tay–Sachs
disease),2 and by Phillipe Gaucher (1882) (Gaucher
disease),3 the biochemical nature of the accumulated
products was only elucidated some 50 years later
(1934) in the latter, as glucocerebroside.4 Considerably
more time was then required for the demonstration by
Hers (1963) that there was a link between an enzyme
deficiency and a storage disorder (Pompe disease).5 In
the following years, the elucidation of several enzyme
defects led to the initial classification of the various
types of LSDs according to their clinical pictures,
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pathological manifestations and the biochemical
nature of the undegraded substrates. Although part of
this classification is still maintained, it is continually
updated on the basis of newly acquired knowledge on
the underlying molecular pathology.
At present, more than 50 LSDs are known. The
majority of these result from a deficiency of specific
lysosomal enzymes. In a few cases, non-enzymatic
lysosomal proteins or non-lysosomal proteins involved
in lysosomal biogenesis are deficient.
The common biochemical hallmark of these dis-
eases is the accumulation of undigested metabolites
in the lysosome. This can arise through several
mechanisms as a result of defects in any aspect of
lysosomal biology that hampers the catabolism of
molecules in the lysosome, or the egress of naturally
occurring molecules from the lysosome. Lysosomal
accumulation activates a variety of pathogenetic cas-
cades that result in complex clinical pictures charac-
terised by multi-systemic involvement.6–10
Phenotypic expression is extremely variable, as it
depends on the specific macromolecule accumu-
lated, the site of production and degradation of the
specific metabolites, the residual enzymatic
expression and the general genetic background of
the patient. Many LSDs have phenotypes that have
been recognised as infantile, juvenile and adult.7
Table 1 summarises the various defective pro-
teins, the type(s) of main accumulated metabolites
and the distinct genes responsible for each specific
LSD type/subtype. It also reports screening and
diagnostic tests available for each disease.
The endo-lysosomal system
The original concept that the lysosome is only one
component of a series of unconnected intracellular
organelles of the endo-lysosomal system12 has been
widely modified by recent studies. Lysosomal func-
tion is now considered in the larger context of the
endosomal/lysosomal system.13 In this highly
dynamic system, which mediates the internalisation,
recycling, transport and breakdown of cellular/extra-
cellular components and facilitates dissociation of
receptors from their ligands, the lysosome represents
the greater degradative compartment of endocytic,
phagocytic and autophagic pathways. Although
hydrolytic enzymes are present in endosomes and
lysosomes, they function optimally in the lysosome,
as it is the most acidic compartment.
Lysosomal enzymes: Synthesis and
trafficking
The lysosomal enzymes, which are synthesised in
the rough endoplasmic reticulum (ER), move
across the ER membrane to the lumen of the ER
via an N-terminal signal sequence-dependent trans-
location. Once in the ER lumen, they are
N-glycosylated and their signal sequence is cleaved.
They then proceed to the Golgi compartment and,
at this stage, the lysosomal enzymes, which require
the mannose 6-phosphate (M6P) marker to enter
the lysosome, acquire the M6P ligand by the
sequential action of a phosphotransferase and a
diesterase.14–16 The receptor–protein complex
then moves to the late endosome, where dis-
sociation occurs; the hydrolase translocates into the
lysosome and the receptor is recycled either to the
Golgi apparatus or to the plasma membrane.
The final steps in the maturation of the lysosomal
enzyme include proteolysis, folding and aggregation.
Not all lysosomal enzymes depend on the M6P
pathway, however. Recently, it has been shown that
the lysosomal integral membrane protein type 2
(LIMP-2)—a ubiquitously expressed transmembrane
protein mainly found in the lysosomes and late
endosomes—is a receptor for lysosomal M6P-
independent targeting of glucocerebrosidase.17
Figure 1 depicts a simplified scheme of M6P-
dependent enzymes sorting to the lysosome.
Epidemiology
To date, worldwide epidemiological data on LSDs
are not available or are limited to distinct popu-
lations. Apart from selected populations presenting
a high prevalence for specific diseases, such as the
Ashkenazi Jewish population at high risk for Gaucher
disease,18 Tay–Sachs disease and Niemann–Pick
disease;19 the Finnish population with its high
incidence of aspartylglucosaminuria20 and infantile/
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Table 1. Lysosomal storage disorders
OMIM Disease Defective protein Main storage
materials
Preliminary
test
Gene
symbol
MIM
ID
Diagnostic
test
Mucopolysaccharidoses (MPSs)
607014
607015 607016
MPS I (Hurler, Scheie,
Hurler/Scheie)
a-Iduronidase Dermatan sulphate,
heparan sulphate
GAGs (U) IDUA 252800 BGT, MGT
309900 MPS II (Hunter) Iduronate sulphatase Dermatan sulphate,
heparan sulphate
GAGs (U) IDS 309900 BGT, MGT
252900 MPS III A (Sanfilippo A) Heparan sulphamidase Heparan sulphate GAGs (U) SGSH 605270 BGT, MGT
252920 MPS III B (Sanfilippo B) Acetyl a-glucosaminidase Heparan sulphate GAGs (U) NAGLU 609701 BGT, MGT
252930 MPS III C ( Sanfilippo C) Acetyl CoA: a-glucosaminide
N-acetyltransferase
Heparan sulphate GAGs (U) HGSNAT 610453 BGT, MGT
252940 MPS III D (Sanfilippo D) N-acetyl
glucosamine-6-sulphatase
Heparan sulphate GAGs (U) GNS 607664 BGT, MGT
253000 MPS IVA (Morquio A) Acetyl
galactosamine-6-sulphatase
Keratan sulphate,
chondroiotin
6-sulphate
GAGs (U) GALNS 612222 BGT, MGT
253010 MPS IV B (Morquio B) b-Galactosidase Keratan sulphate GAGs (U) GLB1 611458 BGT, MGT
253200 MPS VI
(Maroteaux–Lamy)
Acetyl galactosamine
4-sulphatase (arylsulphatase B)
Dermatan sulphate GAGs (U) ARSB 611542 BGT, MGT
253220 MPS VII (Sly) b-Glucuronidase Dermatan sulphate,
heparan sulphate,
chondroiotin
6-sulphate
GAGs (U) GUSB 611499 BGT, MGT
601492 MPS IX (Natowicz) Hyaluronidase Hyluronan – HYAL1 607071 BGT, MGT
Sphingolipidoses
301500 Fabry a-Galactosidase A Globotriasylceramide – GLA 300644 BGT, MGT
228000 Farber Acid ceramidase Ceramide – ASAH1 613468 BGT, MGT
230500 230600
230650
Gangliosidosis GM1
(Types I, II, III)
GM1-b-galactosidase GM1 ganglioside,
Keratan sulphate,
oligos, glycolipids
Oligos (U) GLB1 611458 BGT, MGT
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Table 1. Continued
OMIM Disease Defective protein Main storage
materials
Preliminary
test
Gene
symbol
MIM
ID
Diagnostic
test
272800 Gangliosidosis GM2,
Tay-Sachs
b-Hexosaminidase A GM2 ganglioside,
oligos, glycolipids
– HEXA 606869 BGT, MGT
268800 Gangliosidosis GM2,
Sandhoff
b-Hexosaminidase A þ B GM2 ganglioside,
oligos
– HEXAB 606873 BGT, MGT
230800
230900 231000
Gaucher
(Types I, II, III)
Glucosylceramidase Glucosylceramide Chitoþ (S) GBA 606463 BGT, MGT
245200 Krabbe b-Galactosylceramidase Galactosylceramide – GALC 606890 BGT, MGT
250100 Metachromatic
leucodystrophy
Arylsulphatase A Sulphatides Sulphatides
(U)
ARSA 607574 BGT, MGT
257200 607616 Niemann–Pick
(type A, type B)
Sphingomyelinase Sphingomyelin – SMPD1 607608 BGT, MGT
Olygosaccharidoses (glycoproteinoses)
208400 Aspartylglicosaminuria Glycosylasparaginase Aspartylglucosamine Oligos (U) AGA 613228 BGT, MGT
230000 Fucosidosis a-Fucosidase Glycoproteins,
glycolipids,
Fucoside-rich oligos
Oligos (U) FUCA1 612280 BGT, MGT
248500 a-Mannosidosis a-Mannosidase Mannose-rich oligos Oligos (U) MAN2B1 609458 BGT, MGT
248510 b-Mannosidosis b-Mannosidase Man(b1! 4)GlnNAc Oligos (U) MANBA 609489 BGT, MGT
609241 Schindler N-acetylgalactosaminidase Sialylated/
asialoglycopeptides,
glycolipids
Oligos (U) NAGA 104170 BGT, MGT
256550 Sialidosis Neuraminidase Oligos, glycopeptides Bound SA (U),
Oligos (U)
NEU1 608272 BGT, MGT
Glycogenoses
232300 Glycogenosis II/ Pompe a1,4-glucosidase (acid maltase) Glycogen CK (S) GAA 606800 BGT, MGT
Lipidoses
278000 Wolman/CESD Acid lipase Cholesterol esters – LIPA 613497 BGT, MGT
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Table 1. Continued
OMIM Disease Defective protein Main storage
materials
Preliminary
test
Gene
symbol
MIM
ID
Diagnostic
test
Non-enzymatic lysosomal protein defect
272750 Gangliosidosis GM2,
activator defect
GM2 activator protein GM2 ganglioside,
oligos
– GM2A 613109 MGT
249900 Metachromatic
leucodystrophy
Saposin B Sulphatides Sulphatides
(U)
PSAP 176801 MGT
611722 Krabbe Saposin A Galactosylceramide – PSAP 176801 MGT
610539 Gaucher Saposin C Glucosylceramide – PSAP 176801 MGT
Transmembrane protein defect
Transporters
269920
604369
Sialic acid storage
disease; infantile form
(ISSD) and adult form
(Salla)
Sialin Sialic acid Free SA (U) SLC17A5 604322 MGT
219800 Cystinosis Cystinosin Cystine – CTNS 606272 MGT
257220 Niemann–Pick Type C1 Niemann–Pick type 1 (NPC1) Cholesterol and
sphingolipids
Chitoþ (S) NPC1 607623 Filipin test,
MGT
607625 Niemann–Pick, Type C2 Niemann–Pick type 2 (NPC2) Cholesterol and
sphingolipids
Chitoþ (S) NPC2 601015 Filipin test,
MGT
Structural Proteins
300257 Danon Lysosome-associated
membrane protein 2
Cytoplasmatic debris
and glycogen
– LAMP2 309060 MGT
252650 Mucolipidosis IV Mucolipin Lipids – MCOLN1 605248 MGT
Lysosomal enzyme protection defect
256540 Galactosialidosis Protective protein cathepsin A
(PPCA)
Sialyloligosaccharides Bound SA (U),
Oligos (U)
CTSA 613111 BGTa, MGT
Post-translational processing defect
272200 Multiple sulphatase
deficiency
Multiple sulphatase Sulphatides,
glycolipids, GAGs
Sulphatides (U),
GAGs (U)
SUMF1 607939 BGTb, MGT
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Table 1. Continued
OMIM Disease Defective protein Main storage
materials
Preliminary
test
Gene
symbol
MIM
ID
Diagnostic
test
Trafficking defect in lysosomal enzymes
252500
252600
Mucolipidosis IIa/b,
IIIa/b
GlcNAc-1-P transferase Oligos, GAGs, lipids Oligos (U) GNPTAB 607840 BGTc, MGT
232605 Mucolipidosis IIIg GlcNAc-1-P transferase Oligos, GAGs, lipids Oligos (U) GNPTG 607838 BGTc, MGT
Polypeptide degradation defect
265800 Pycnodysostosis Cathepsin K Bone proteins X-ray CTSK 601105 MGT
Neuronal ceroid lipofuscinoses (NCLs)
256730 NCL 1 Palmitoyl protein thioesterase
(PPT1)
Saposins A and D Ultrastructure PPT1 600722 BGT, MGT
204500 NCL 2 Tripeptidyl peptidase 1 (TPP1) Subunit c of ATP
synthase
Ultrastructure TPP1 607998 BGT, MGT
204200 NCL 3 CLN3, lysosomal
transmembrane protein
Subunit c of ATP
synthase
Ultrastructure CLN3 607042 MGT
256731 NCL 5 CLN5, soluble lysosomal
protein
Subunit c of ATP
synthase
Ultrastructure CLN5 608102 MGT
601780 NCL 6 CLN6, transmembrane protein
of ER
Subunit c of ATP
synthase
Ultrastructure CLN6 606725 MGT
610951 NCL 7 CLC7, lysosomal chloride
channel
Subunit c of ATP
synthase
Ultrastructure MFSD8 611124 MGT
600143 NCL 8 CLN8, transmembrane protein
of endoplasmic reticulum
Subunit c of ATP
synthase
Ultrastructure CLN8 607837 MGT
610127 NCL 10 Cathepsin D Saposins A and D Ultrastructure CTSD 116840 MGT
Abbreviations: CK, creatine kinase; CLN, ceroid lipofuscinosis, neuronal; GAGs, glysosaminoglycans; GLcNAc-1-P transferese, N-acetylglucosamine-1-phosphotransferese; Oligos, oligosaccharides; S, serum; SA, sialic acid; U,
urine; Chito, chitotriosidase
aDefect of b-galactosidase and neuraminidase and/or cathepsin A
bDecrease in some lysosomal and non-lysosomal sulphatases
cSome lysosomal hydrolase activities increased in plasma and decreased in cultured fibroblasts
†Note that 5–7 per cent of the population have a recessively inherited defect in the chitotriosidase gene, which leads to false-negative values.11
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juvenile neuronal ceroid lipofuscinosis,21 as far as we
know, prevalence data on LSDs, as a group, have only
been reported in Greece,22 the Netherlands,23
Australia,24 Portugal25 and the Czech Republic.26 As
a group, overall incidence of LSDs is estimated at
around 1:5,000–1:8,000.24
Classification: From the nature of the
primary stored material to the type
of molecular defect
LSDs can be grouped according to various classifi-
cations. While, in the past, they were classified on
the basis of the nature of the accumulated sub-
strate(s), more recently they have tended to be
classified by the molecular defect (Table 1). A
classic example of LSDs grouped by storage is the
group of mucopolysaccharidoses, resulting from a
deficiency of any one of 11 lysosomal enzymes that
are involved in the sequential degradation of glyco-
saminoglycans (or mucopolysaccharides). In the
group of sphingolipidoses, undegraded sphingoli-
pids accumulate due to an enzyme deficiency or to
an activator protein defect (the latter is classified in
Table 1 as a group according to the molecular
defect). Among the oligosaccharidoses (also known
as glycoproteinoses), a single lysosomal hydrolase
deficiency causes storage of oligosaccharides. In
some cases, a deficiency in a single enzyme can
result in the accumulation of different substrates.
For example, GM1 gangliosidosis and Morquio-B
disease are both caused by an acid b-galactosidase
activity defect, yet results in GM1 ganglioside and
keratan sulphate accumulation, respectively.
Table 1 also reports the emerging classification of
diseases based on the recent understanding of the
molecular basis LSDs. This subset includes groups
of disorders due to: (i) non-enzymatic lysosomal
protein defects; (ii) transmembrane protein defects
(transporters and structural proteins); (iii) lysosomal
enzyme protection defects; (iv) post-translational
processing defects of lysosomal enzymes; (v) traf-
ficking defects in lysosomal enzymes; and (vi) poly-
peptide degradation defects. Finally, another group
includes the neuronal ceroid lipofuscinoses (NCLs),
which are considered to be lysosomal disorders,
even though distinct characteristics exist. While, in
the classic LSDs, the deficiency or dysfunction of
an enzyme or transporter leads to lysosomal
accumulation of specific undegraded substrates or
metabolites, accumulating material in NCLs is not
a disease-specific substrate but the subunit c of
mitochondrial ATP synthase or sphingolipid activa-
tor proteins A and D.27
Figure 1. Simplified scheme of M6P-dependent enzymes sorting to the lysosome. The enzyme UDP-N-acetylglucosamine-1-phosphotransferase,
responsible for the initial step in the synthesis of the M6P recognition markers, plays a key role in lysosomal enzyme trafficking. Loss of this activity
results in mucolipidoses II/III. Note that not all lysosomal enzymes depend on the M6P pathway.
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Multiple sulphatase deficiency (MSD) is also worth
mentioning. It has been shown that MSD results from
a post-translational processing defect due to the failure
of the Ca-formylglycine-generating enzyme to
convert a specific cysteine residue, at the catalytic
centre of all sulphatases, to a Ca-formylglycine
residue.28,29 Another rare LSD, galactosialidosis, is
associated with the defective activity of two enzymes,
b-galactosidase and sialidase. In these diseases—
classified as ‘lysosomal enzyme protection defects’—a
multi-enzyme complex between the two lysosomal
enzymes and the protective protein, cathepsin A
(PPCA), forms improperly.30
The breakdown of certain glycosphingolipids by
their respective hydrolases requires the presence of
activator proteins, known as sphingolipid activator
proteins or saposins, encoded by two different
genes. The defective function of the GM2 activator
protein results in the AB variant of GM2 gangliosi-
dosis.31 The prosaposin is processed to four hom-
ologous saposins (Sap A, Sap B, Sap C and Sap
D).32 Deficiency of Sap A, Sap B and Sap C results
in variant forms of (i) Krabbe disease, involving
abnormal storage of galactosylceramide;33 (ii) meta-
chromatic leucodystrophy (MLD), associated with
sulphatide storage;34 and (iii) Gaucher’s disease,
involving glucosylceramide storage,35 respectively.
Rarely, a total deficiency of prosaposin has been
reported, resulting in a very severe phenotype.36
Mucolipidoses result from defects in the
enzymeUDP-N-acetylglucosamine-1-phosphotran-
sferase, which plays a key role in lysosomal enzyme
trafficking.37 This enzyme is responsible for the
initial step in the synthesis of the M6P recognition
markers essential for receptor-mediated transport of
newly synthesised lysosomal enzymes to the endo-
somal/prelysosomal compartment (Figure 1).
Failure to attach this recognition signal leads to the
mistargeting of all lysosomal enzymes that require
the M6P marker to enter the lysosome.
Laboratory diagnosis
Like other metabolic diseases, LSDs show remark-
ably varied clinical signs and symptoms, which may
occur from the in utero period to late adulthood,
depending on the complexity of the storage pro-
ducts and differences in their tissue distribution.
Indeed, the recognition of LSD clinical features
requires clinical expertise, as most of them are not
specific and can be caused by defects in other
metabolic pathways (mitochondrial and peroxiso-
mal), or by environmental factors. Even in the pres-
ence of typical clinical signs and symptoms, samples
and diagnostic tests are different for each group of
lysosomal disorders and often are specific to a given
disease.
The definitive diagnosis of LSDs therefore
requires close collaboration between laboratory
specialists and clinicians. For laboratory diagnosis,
the clinician must select the appropriate test to be
performed on the basis of a comprehensive evalu-
ation that includes not only a physical assessment of
the patient but also paraclinical test results (periph-
eral blood smears, radiological/neurophysiological
findings etc). Additionally, each sample that is sent
for testing should be accompanied by a detailed
patient case history and family history, to allow the
laboratory specialist to make a reliable evaluation of
the results that might include indications for other
potential investigations.
Before considering specific analyses (enzymatic
and/or molecular), preliminary screening tests
should be performed (Table 1). Increased urinary
excretion of glycosaminoglycans is mainly found in
the mucopolysaccharidoses group, while abnormal
urinary oligosaccharide excretion patterns mostly
characterise the oligosaccharidoses (glycoprotei-
noses). There are also more specific preliminary
tests, such as the qualitative assessment of urinary
sulphatide storage, which can give indications for
MLD (due to arylsulphatase A enzyme deficiency
or saposin B activator defect); increased urinary
excretion of free sialic acid is suggestive of the sialic
acid storage disorders (the severe infantile form
[ISSD] or the slowly progressive adult form [Salla]).
Abnormal serum levels of metabolites/proteins can
be used as ancillary tests in some LSDs. Serum cre-
atine kinase (CK) concentrations can be elevated
in Pompe disease, while high levels of chitotriosi-
dase can indicate Gaucher disease and, to a lesser
extent, other lipidoses, such as Niemann–Pick C
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(NPC). All of these preliminary (urine and serum)
tests carry the risk of producing false positives/
negatives, however, and need to be followed up
with specific enzymatic and/or molecular analyses
performed on suitable samples, leucocytes and/or
cell lines (fibroblasts and/or lymphoblasts).
As about 75 per cent of LSDs are due to a
deficiency in lysosomal hydrolase activity, the dem-
onstration of reduced/absent lysosomal hydrolase
activity by a specific enzyme assay is an effective
and reliable method of diagnosis. In these cases,
molecular analysis can refine the enzymatic diagno-
sis. The remaining LSDs, resulting from
non-enzymatic protein defects, require molecular
analysis to be performed on the specific gene for a
conclusive diagnosis (Table 1).
Generally, an inherited deficiency of a lysosomal
enzyme is associated with an LSD. There are,
however, individuals who show greatly reduced
enzyme activity but remain clinically healthy. This
condition, termed as enzymatic ‘pseudodeficiency’
(Pd), is known in some lysosomal hydrolases.
Conversely, there are circumstances in which
affected individuals with a clinical/paraclinical
picture resembling some glycosphingolipidoses
show normal activity of the relevant lysosomal
enzyme. These patients should be investigated for a
potential defect of an activator protein involved in
glycosphingolipid breakdown.
Pseudodeficiency
To date, Pds due to polymorphic genetic variants, have
been reported for at least nine lysosomal enzymes,
including: arylsulphatase A (ARSA gene),38
b-hexosaminidase (HEXA gene),39 a-iduronidase
(IDUA gene),40 a-glucosidase (GAA gene),41
a-galactosidase (GLA gene),42,43 b-galactosidase
(GLB1 gene),44 a-fucosidase (FUCA1 gene)45 and
b-glucuronidase (GUSB gene).46,47
While some of these genetic conditions are rare,
the arylsulphatase A Pd has been estimated to have
a frequency of 7.3–15 per cent.48–50 Since the Pd
allele is more frequent than the alleles causing MLD
(estimated to be 0.5 per cent), individuals present-
ing with neurological symptoms and homozygous
for arylsulphatase A Pd are likely to be misdiag-
nosed as MLD.51 Additionally, it should be noted
that Pd polymorphisms can occur on the same gene
as MLD-causing mutations. It is therefore necessary
to perform a combination of enzymatic and mol-
ecular analyses to determine the actual genetic
make-up of MLD patients and their family
members, in order to distinguish individuals carry-
ing Pd alleles from those carrying MLD alleles.
Activator proteins
Another complication that can potentially lead to
missed diagnoses is represented by defects of those
cofactors (mentioned above) required for the func-
tion of certain lysosomal enzymes involved in glyco-
sphingolipid breakdown. Variant forms of GM2
gangliosidosis, Krabbe disease, MLD and Gaucher
disease can result not only from a deficiency of an
enzymatic activity, but also from defects of sphingo-
lipid activator proteins or saposins.52 In these cases,
conclusive diagnosis requires a comprehensive evalu-
ation based on a range of diagnostic procedures,
including neuroradiological, neurophysiological,
biochemical/enzymatic and molecular tests.53
Biochemical genetic testing
Biochemical genetic testing (BGT), including the
assay of enzymatic proteins, is feasible for most
LSDs and is essential for the diagnosis of primary
lysosomal enzyme deficiency.
Lysosomal enzymes are present in almost all
tissues and biological samples. The choice of the
sample type to be analysed is based on (i) the level
of an enzyme’s activity in a specific tissue, (ii) the
sample stability during its transfer to the referring
laboratory and (iii) the time of diagnosis.
Although enzyme activity can be assayed in
some biological fluids, such as plasma, serum and
urine, several enzymatic Pds have been reported in
serum or plasma, so their use can lead to pitfalls in
diagnosis.43,54
Leucocytes are often appropriate biological
samples, although possible interference between
isoenzymes should be taken into consideration.
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Fibroblast samples represent the gold standard in
diagnosis, since they express the optimum enzyme
activity; however, they require an invasive skin
biopsy and culturing. Epstein–Barr virus-
transformed B-lymphoblast culture obtained from a
non-invasive blood sampling can be useful, bearing
in mind, however, that lymphoblasts do not express
some enzymatic activities, such as arylsulphatase
A. Lysosomal enzyme assays are usually performed
using synthetic (fluorimetric or colorimetric) sub-
strates which show undetectable or very low
enzyme activity in cell lines of affected individuals.
The complete absence of lysosomal enzyme
activity generally confirms diagnosis. Conversely,
the presence of normal lysosomal enzyme activity
cannot exclude a specific diagnosis if it is
accompanied by suggestive clinical symptoms and/
or the abnormal presence of metabolites in the
urine and/or storage in peripheral smear and/or
tissue biopsy. For example, a patient who presents
with a clinical profile resembling Gaucher disease,
with high levels of chitotriosidase activity and
increased concentrations of glucosylceramide in
plasma and normal b-glucosidase activity in skin
fibroblasts, should be referred for a molecular
genetic study of the prosaposin gene (PSAP),
which codes for the cofactor Sap C required for
the function of b-glucosidase.55 Findings of normal
arylsulphatase A activity and abnormal patterns of
urinary sulphatides in a suspected MLD patient do
not exclude the disease and should be followed up
by the molecular analysis of PSAP.52,53 The detec-
tion of residual lysosomal enzyme activity should
be carefully evaluated, together with clinical and
instrumental findings. Molecular genetic testing
(MGT) can reveal polymorphisms that potentially
lead to an enzymatic Pd.
Molecular genetic testing
MGT performed on DNA and/or RNA comprises
a range of different molecular approaches for inves-
tigating the entire gene-coding regions and exon–
intron boundaries, as well as 50- and 30-untranslated
regions (UTRs). It can confirm the enzymatic diag-
nosis of an LSD, and is essential for the definitive
diagnosis of LSDs resulting from non-enzymatic
lysosomal proteins (Table 1) and in post-mortem
diagnoses when the only suitable specimens avail-
able are DNA samples. MGT can also contribute to
elucidating the findings of high biochemical residual
enzyme activity in affected patients and very low
enzyme activities in unaffected patients (enzymatic
Pds).38–47 Moreover, it is useful in genotype–phe-
notype correlation studies for some diseases and for
indentifying at-risk family members.
MGT can clarify the type of genetic variation
and its impact on the protein and on the presence
of residual enzyme activity. This information is
crucial in evaluating treatment options, such as
enzyme replacement therapy (ERT), to date only
available for some disorders, and alternative treat-
ments such as pharmacological chaperones or sub-
strate reduction therapy (SRT), for which clinical
trials are still in progress.56,57
Particular care should be taken when interpreting
genotype–phenotype correlations, even in the
context of a recurrent mutation, as some patients
carrying the same lesion may present with different
clinical phenotypes, suggesting that other factors,
such as polymorphic variants, genetic modifiers or
RNA editing-like mechanisms,58 can lead to
changes in protein function which could influence
the clinical phenotype.
In general, the interpretation of a molecular result
should depend on a comprehensive evaluation that
includes related clinical, paraclinical and biochemical
data. For instance, additional molecular studies are
needed in the case of an ascertained enzymatic
deficiency that is not supported by the detection of
the underlying genetic lesion in a patient with a
picture suggestive of an LSD. Expression gene profil-
ing and RNA and/or protein analyses can be
helpful in revealing deletions/insertions, gross
rearrangements and potential transcription defects.
In these patients only the RNA analysis and real-
time polymerase chain reaction permitted to reveal
the underlying pathogenetic mechanism of Fabry
disease. Indeed, the analyses identified an impressive
reduction of the predominantly expected alpha-
galactosidase A mRNA transcript (encoding the
lysosomal enzyme) in addition to the overexpression
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of an alternatively spliced, weakly regulated, alpha-
galactosidase A transcript. Deeply intronic mutations,
missed by conventional DNA sequence analysis,
were subsequently found to cause the unbalanced
ratio of alpha-galactosidase A mRNAs leading to a
newly pathogenetic mechanism of Fabry disease by
the alteration of the transcription process.59,60
The detection of a known mutation should also
be supported by a comparison of the patient’s bio-
chemical and clinical data with those available in
the literature. For instance, a genotype–phenotype
miscorrelation could signal incorrect genotyping.
Reports of an additional nucleotide change in cis
on a mutated allele, which potentially modifies the
phenotype, are not infrequent. A somatic mosai-
cism was reported to be the underlying molecular
mechanism for an unexpectedly severe form of
Gaucher disease (type 2) in a patient in whom the
beneficial effect of the mild p.N409S (traditionally
named as N370S) mutation was experimentally
demonstrated to be reversed by the in cis presence
of the severe p.L483P (traditionally named as
L444P) mutation.61 A modulating action was also
reported for a novel polymorphism (p.L436F),
identified in cis with the known p.R201C
mutation, in a patient affected by the juvenile form
of GM1 gangliosidosis with a severe outcome. In
vitro expression studies and Western blot analysis
showed that the novel polymorphism dramatically
abrogated the residual enzyme activity predicted to
be associated with the common p.R201C
mutation, explaining the severe outcome.62
Conventional MGT techniques have also been
reported to be responsible for accidental misgeno-
typing of patients in cases of genomic lesions such
as insertion/deletions, complex rearrangements and
uniparental disomy. In particular, additional tech-
niques were necessary to ascertain various gene–
pseudogene rearrangements in Hunter syndrome
patients which had been missed by conventional
methods.63 Partial/total gene deletions and various
gene–pseudogene rearrangements led to incorrect
genotyping in Gaucher disease during routine diag-
nostic mutation analysis.64,65
Finally, it is important to underline that MGT
results should be interpreted with caution, even in
the presence of a change previously reported as a
disease-causing mutation. For years, the c.1151G.
A (p.S384N) mutation was considered to be disease-
causing in patients with Maroteaux–Lamy syn-
drome but, recently, segregation studies in a family
at risk for the syndrome conclusively revealed
c.1151G. A (p.S384N) to be a polymorphism.66
Screening tests on dried blood spot
specimens
The availability of analyses of acylcarnitines and
amino acids using liquid chromatography–tandem
mass spectrometry technology on dried blood spot
specimens (DBS) led to screening for treatable
inborn errors of metabolisms (IEM) in newborns.
At present, the expanded newborn screening based
on DBS identifies more then 30 IEM and rep-
resents an important step forward.67
A few years ago, screening tests for several LSDs
by BGT on DBS using fluorescent methods68–70
were reported. Subsequently, multiplex assays of
lysosomal enzymes on DBS by tandem mass spec-
trometry have been described.71–73
The availability of multiplex technology has
facilitated the technical aspects of testing, making it
easier to identify LSDs and to introduce newborn
screening programmes for treatable LSDs.74–76
Attempts to widen screening programmes to
include other LSDs are essential for patients in
whom an early and presymptomatic diagnosis can
provide better outcomes by reducing clinically sig-
nificant disabilities.77
Obviously, reduced residual enzyme activity
detected in a presymptomatic patient at newborn
screening also should be investigated by standard
laboratory diagnostic procedures.
Genetic counselling
All LSDs are inherited as autosomal recessive traits,
except for Fabry disease, Hunter syndrome (or
mucopolysaccharidosis II) and Danon disease.
These are X-linked disorders.
Once the laboratory diagnosis (enzymatic and/or
molecular) of an LSD patient is ascertained, genetic
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counselling for at-risk couples includes prenatal testing
on chorionic villi (at 11–12 weeks) or amniocytes (at
16 weeks). Genotyping individual LSD patients also
allows carriers in the family to be identified and can
sometimes predict phenotypes in the patients.
Biobanking
Sample and clinical/instrumental data banking is
important for all rare genetic diseases—including
LSDs—which often lead to death at an early age.
Since it is likely that our understanding of genes,
diseases and testing methodology will improve in
the future, consideration should be given to bio-
banking appropriate biological material from
patients affected or suspected to be affected by
LSDs, as well as from their parents and other first-
degree relatives, for future diagnostic and research
purposes.
Biological material such as urine, whole blood,
plasma, serum, leucocytes, DNA and cell lines
(fibroblasts from skin biopsy and/or lymphoblasts
from blood) should be stored. Effective interaction
between clinicians and biobank staff is essential,
since future results rely not only on the availability
of appropriate biological samples, but also on the
accurate recording of associated clinical/paraclinical
data.
Hydrops foetalis, an extreme presentation of
many LSDs, represents the best example of a
complex case in which diagnosis can be achieved
only if appropriate samples are stored. Indeed,
hydrops foetalis can be associated with a wide spec-
trum of phenotypes, including mucopolysacchari-
dosis VII and IVA, Gaucher disease, sialidosis, GM1
gangliosidosis, galactosialidosis, ISSD, Niemann–
Pick disease type C (and A), mucolipidosis II
(I-cell disease), Wolman disease and disseminated
lipogranulomatosis (Farber disease).78 Frequently,
these LSDs are only recognised after the recurrence
of hydrops foetalis in several pregnancies.79,80 In
order to arrive at a conclusive diagnosis and to
optimise the storage of the most appropriate bio-
logical material in such complex cases, many skilled
experts, including clinicians, genetics, biochemists,
molecular biologists etc, must cooperate.
Conclusions
In conclusion, BGT and MGT must be considered
as complementary analyses for the diagnosis of
most LSDs, for genotype–phenotype correlations
and for prenatal diagnosis. MGT is essential for
carrier detection, and can sometimes predict prog-
nosis and support therapeutic choices, including
the application of new therapeutic approaches.
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